China Life Sciences Health Industry Client Briefing – February 2013 (March 11, 2013)

by Reed Smith

Pharmaceuticals, Medical Devices, Health Care & Life Sciences

News & Regulations

New Drug GSP Issued: Supervision on Drug Distribution to be Enhanced (China Securities Journal 2013-02-20) – February 20, 2013

The State Food & Drug Administration (SFDA) issued revised Good Supply Practices of Drugs (New GSP), effective June 1, 2013, to upgrade the current requirements for drug distribution and supply chain management in China. The New GSP consists of 187 articles, spanning four chapters, and adds requirements regarding the following:

  • Information Management: The New GSP sets forth detailed requirements for computer management facilities, network environments, databases, and application software. To ensure electronic monitoring of drug products, distributors must establish local area networks, information platforms, and computer systems.
  • Cold Chain Management: Distributors of the raw material for traditional Chinese medicine (TCM) and herbal slices must establish dedicated warehouse and maintenance locations. Drug distributors engaged in the distribution of chilled and frozen products must be equipped with cold storage systems, monitoring and alert equipment, spare power supply, and refrigerated vehicles and incubators.
  • Transportation Management: A drug distributor must review the qualifications of, and sign liability agreements with, any third party engaged in the transport of its drug products.
  • Sales Records Management: A drug distributor must keep documentation of the delivery and transport of drug products, including the issuance of invoices for any drug procurement.

The SFDA has set a three-year transition period for drug distributors to comply with the requirements set forth in the New GSP. Drug distributors not in compliance with the revised requirements by the prescribed deadline may be banned from their drug distribution operations in China.

China to Encourage Innovative Drug Development (Xinhua News Agency 2013-02-27) – February 27, 2013

To encourage the innovative research and development of new drugs, the SFDA recently announced a plan to reform the drug examination and registration process for both new and generic drugs. To further streamline the drug approval process for new drugs, the SFDA intends to encourage development by focusing on clinical value and by shortening the approval process for those drugs developed from self-owned intellectual property rights. The SFDA will give priority to some generic drugs during the drug approval process, such as those in short supply or those used to treat rare diseases. The plan also calls for more stringent quality control for clinical trials, including additional protection for clinical trial subjects. Finally, the SFDA intends to encourage the research and development of drugs used by children.

Baidu, SFDA, Team Up on Drug Search (Global Times 2013-02-25) – February 26, 2013

In a bid to crack down on false drug information posted on the Internet,, China’s largest Internet search engine, has partnered with the SFDA to clean up the data generated through online searches of medicines and online drugstores. Online search results on Baidu will provide detailed information obtained from the SFDA about medicine specifications and licensed drug producers.

TCM Manufacturer Urged to Raise Awareness of Drug Side Effects (Xinhua News Agency 2013-02-07) – February 7, 2013

Following a recall of Yunnan Baiyao, a TCM product used to treat open wounds and muscle pain, the SFDA has ordered the manufacturer to raise public awareness of the product’s side effects. The Department of Health of the Hong Kong Special Administrative Region recently recalled Yunnan Baiyao after finding that it contains an undeclared amount of aconitum alkaloids, which, if ingested improperly, may cause some side effects.

Favorable Policies Support Biopharmaceutical Stocks (China Daily 2013-02-08) – February 16, 2013

According to industry observers, China’s encouraging policies for the biological industry are supporting the country’s share prices in the biopharmaceutical sector. The 12th Five-Year Development Plan for the Biological Industry, issued by the National Development and Reform Commission – China’s top economic planner – indicates that the biological pharmaceutical sector is one of the seven key industries that China will support by 2020.

Medical Firms See Healthy Foreign Trade Growth (China Daily 2013-02-06) – February 6, 2013

Statistics recently released by the China Chamber of Commerce for Import & Export of Medicine & Health Products, an organization under the Ministry of Commerce, indicate that the export and import volume of China’s medical industry totaled $80.95 billion in 2012, a record growth of 10.5 percent. The Chamber expects this figure to surge even higher, to 12 percent, for 2013.

China's Medical Device Market to Grow Rapidly (Xinhua News Agency 2013-02-05) – February 5, 2013

The increasing demand for the upgrade of outmoded medical devices in Chinese hospitals is expected to spur rapid growth of the medical device market. According to a China Med 2013 press conference – an annual international exhibition for medical devices – 60 percent and 15 percent of the medical devices installed in the country’s 175,000 health institutions are dated from the mid-1980s and 1970s, respectively.

Implementing Programs for Serious Illness Health Insurance Issued in Several Provinces (People’s Daily 2013-02-17) – February 17, 2013

Several provinces, including Qinghai, Shaanxi, Fujian, Zhejiang, Guangxi, Anhui, Shandong, Liaoning and Jilin, have established local programs to assist with the implementation of health insurance policies for serious illnesses. According to the Guiding Opinions Concerning Carrying Out the Serious Illness Health Insurance for Urban and Rural Residents (Opinions), medical insurance participants are entitled to additional reimbursement for expenses incurred from the medical treatment of serious illnesses, as long as the self-paid portion (excluding the basic reimbursement) exceeds the local annual per capita income. The Opinions further require the actual reimbursement rate to be not less than 50 percent of total medical expenses. Following the implementation of the local programs, the actual reimbursement rates in the provinces of Qinghai, Guangxi and Ningxia are expected to reach 80 percent to 90 percent; 53 percent; and 50 percent to 81 percent, respectively. In addition, to provide a wider scope of protection, some provinces intend to combine basic medical insurance with serious illness insurance, and medical aid and commercial insurance.

China Forbids Linking Doctors’ Incomes with Patient Medical Expenses (Xinhua News Agency 2013-02-20) – February 21, 2013

The Health Reform Office under the State Council, or China’s Cabinet, recently released guidelines prohibiting hospitals from linking doctors’ incomes with their patients’ medicine and medical exam expenses. Because some hospitals link doctors’ incomes with the revenue earned through medication sales and exam fees, which results in greater economic burden for patients, the guidelines are intended to consolidate and improve the basic health care system in China through solutions related to local-level health care reform.

Provinces Urged to Buy Insurance (China Daily 2013-02-22) – February 22, 2013

The Ministry of Health (MOH) recently announced a public insurance program, the New Rural Cooperative Medical Scheme, to help rural residents cope with the costs of medical treatment for severe chronic diseases. The program, which will be independently operated at the provincial level, will spend about 15 yuan ($2.38) per person annually to purchase commercial insurance for farmers in rural areas. This latest measure follows the issuance of a statement in August by the National Development and Reform Commission, the MOH, and four other state-level government agencies, requesting provinces to purchase commercial insurance to help alleviate the heavy financial burden associated with treating severe chronic diseases for rural residents who do not have such coverage.

Written by:

Reed Smith

Reed Smith on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.